Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Has announcements × infigratinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1

Interventions

TIC10 compound 3 trastuzumab deruxtecan 2 umbralisib 1 ublituximab 1 pembrolizumab 1 infigratinib 1 enfortumab vedotin 1 duvelisib 1 blinatumomab 1 belumosudil 1 Rituximab 1 KD025 1 Gemcitabine 1 Crizotinib 1 Cisplatin 1 Carboplatin 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02150967 2023-07-03

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

QED Therapeutics, a BridgeBio company

Phase 2 Terminated

143 enrolled 25 charts 2 FDA

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡